Diagnosing CIDP involves peripheral nervous system testing, cerebrospinal fluid analysis, and imaging. CIDP is an immune-mediated condition affecting your peripheral nerves. It occurs when immune ...

data from the Optum Market Clarity system were gathered for patients with at least 2 claims related to CIDP (separated by 30-365 days), at least 1 nerve conduction test (90 days or more after ...

CIDP, while less acute, is a chronic neurological disorder that similarly impacts mobility. Long-term effects for GBS patients often include chronic pain, muscle weakness, and fatigue, with some ...

FDA approved Vyvgart Hytrulo prefilled syringe for gMG and CIDP self-injection in 20–30 seconds. Human factor studies showed patients and caregivers safely administered the new formulation.

The phase IIb study is evaluating batoclimab in CIDP patients whose disease had worsened during standard-of-care treatment. CIDP is a rare autoimmune neurological disorder that causes progressive ...

He noted the significant early impact on CIDP and progress in clinical milestones, including advancing empasiprubart and efgartigimod into Phase III programs. Van Hauwermeiren announced that 2025 ...

CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International is commemorating Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Awareness ...

Doctors can distinguish CIDP from other neurological conditions in several ways, including using test results, noting when symptoms start, how they progress, and how long they persist. Doctors may ...

While anyone can get CIDP, people in their 50s and 60s, as well as men, are more likely to develop the condition. There’s no test to diagnose CIDP. Instead, your doctor will ask you questions ...